Venus Remedies Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Venus Remedies Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 33% in 3 years; of every extra ₹100 of sales, ₹42 became extra profit. Higher than 88% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.0 times. Higher than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹158Over the last 3 years, every ₹100 of reported profit came with ₹158 of operating cash.
Higher than 74% of Healthcare companies in India.
Self-Funding Ratio
4.0×Over the last 3 years its own operating cash covered its investment spending (capex) 4.0 times.
Higher than 86% of Healthcare companies in India.
Cash Locked Ratio
₹13For every ₹100 of sales, ₹13 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹22 tied up three years earlier.
Less money tied up than 71% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹42Sales grew 33% in 3 years; of every extra ₹100 of sales, ₹42 became extra profit.
Higher than 88% of Healthcare companies in India.
Asset Productivity Ratio
+33% / +42%In 3 years sales changed by +33% while total assets changed by +42%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Higher than 78% of Healthcare companies in India.
Tangible Assets Ratio
89%Of every ₹100 the company owns, ₹89 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 72% of Healthcare companies in India.
Tangible Net Worth Ratio
86%Of every ₹100 of net worth, ₹86 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 68% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Venus Remedies Limited owes ₹0.22 for every ₹1 it owns. Net profit rose 127% in the year to Mar 2026, and grew 57% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
16.6Investors pay ₹16.6 for every ₹1 of Venus Remedies Limited's yearly profit, lower than 88% of Healthcare companies in India.
P/B ratio
2.90The share price is 2.90 times Venus Remedies Limited's book value per share, lower than 72% of Healthcare companies in India.
Market cap
₹1,927 CrThe total market value of all of Venus Remedies Limited's shares at today's price (share price × number of shares), smaller than 68% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹664 CrWhat Venus Remedies Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹496.56Net worth divided by the number of shares. The share price of ₹1,442 is 2.9 times this, which is the P/B above.
Return on equity (ROE)
17.5%Venus Remedies Limited earned 17.5% on its shareholders' money over the last year, higher than 72% of Healthcare companies in India.
Owes vs Owns
0.22×Venus Remedies Limited owes ₹0.22 for every ₹1 it owns (low), lower than 80% of Healthcare companies in India.
Dividend yield
0.62%Venus Remedies Limited pays 0.62% of its share price as dividends a year, higher than 69% of dividend-paying Healthcare companies in India.
Revenue growth
+13%Revenue rose 13% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Profit growth
+127%Net profit rose 127% in the year to Mar 2026, and grew 57% a year on average over 3 years.
Profit margin
14.0%Venus Remedies Limited keeps ₹14 of every ₹100 of revenue as net profit.
Cash quality
1.5×Cash from Venus Remedies Limited's business was 1.5× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
2904.8×Venus Remedies Limited's operating profit covered its interest costs 2904.8 times in the year to Mar 2026.
Cash vs debt
Net cashVenus Remedies Limited held ₹87 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Venus Remedies Limited's P/E ratio?
Investors pay ₹16.6 for every ₹1 of Venus Remedies Limited's yearly profit, lower than 88% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Venus Remedies Limited: ₹1,927 Cr ÷ ₹664 Cr (31 Mar 2026) = 2.9.
What is Venus Remedies Limited's return on equity?
Venus Remedies Limited earned 17.5% on its shareholders' money over the last year, higher than 72% of Healthcare companies in India.
How much does Venus Remedies Limited owe compared with what it owns?
Venus Remedies Limited owes ₹0.22 for every ₹1 it owns (low), lower than 80% of Healthcare companies in India.
Does Venus Remedies Limited pay a dividend?
Yes. Venus Remedies Limited pays 0.62% of its share price as dividends a year, higher than 69% of dividend-paying Healthcare companies in India.
Is Venus Remedies Limited's revenue growing?
Revenue rose 13% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.